NEW YORK (GenomeWeb News) – Seegene announced today that it has signed an agreement with Eidia to market the firm's molecular diagnostic products in Japan.

Under the deal, Eidia, which is the diagnostics subsidiary of Eisai, will have access to Seegene's TOCE (tagging oligonucleotide capture and extension) multiplex molecular diagnostic tests. The Japanese firm will exclusively market and distribute the tests in Japan, and it will seek regulatory clearance from the Japanese Pharmaceutical and Medical Device Agency.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.